IN8bio Reports No New Deaths or Relapses in Phase 1 Trial of Gamma-Delta T Cell Therapy
IN8bio Reports No New Deaths or Relapses in Phase 1 Trial of Gamma-Delta T Cell Therapy
IN8bio报告在伽马-德尔塔t电芯治疗的第一阶段试验中未出现新死亡或复发。
IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced updated data from the ongoing Phase 1 trial of INB-100, an allogeneic, haploidentical gamma-delta T cell therapy in older patients with hematologic malignancies undergoing haploidentical stem cell transplant (HSCT) with reduced intensity conditioning (RIC) at the 2024 American Society of Hematology (ASH) Annual Meeting, being hosted in San Diego, CA.
In8bio, Inc.(纳斯达克:INAB)是一家临床阶段的生物制药公司,正在开发创新的gamma-delta电芯疗法,今天在2024年美国血液学会(ASH)年会上宣布了关于INb-100的最新数据。该治疗是一种全基因相合的gamma-delta电芯疗法,针对正在接受减轻强度预处理(RIC)的基因相合的干细胞移植(HSCT)的老年血液恶性肿瘤患者,会议将在加利福尼亚州圣地亚哥举行。